The provider confirmed on Monday it would refocus investment towards its pathology and clinical trials division in a bid to recover its losses.
The provider confirmed on Monday it would refocus investment towards its pathology and clinical trials division in a bid to recover its losses.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.